Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02687542 · ClinicalTrials.gov registry record · Phase 2
Efficacy, Safety and Tolerability of PF-06649751 in Parkinson's Disease Patients With Motor Fluctuations
A Phase 2 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 2
- Development phase
- 108
- Enrollment target
NCT02687542 is a Phase 2 study that was terminated before completion, run by Pfizer. The registered enrollment target is 108 participants.
The verdict
NCT02687542, a Phase 2 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 108 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy, safety and tolerability of PF-06649751 in Parkinson's disease patients who experience motor-fluctuations.
Interventions
- DRUG Placebo
- DRUG PF-06649751 low dose (1 mg QD)
- DRUG PF-06649751 middle dose 1 (3 mg QD)
- DRUG PF-06649751 middle dose 2 (7 mg QD)
- DRUG PF-06649751 high dose (15 mg QD)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 108 participants |
| Start Date | 2016-03-03 |
| Est. Completion | 2017-11-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02687542
The ClinicalTrials.gov registry entry for NCT02687542 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 108 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Placebo is the first listed.
NCT02687542 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02687542 about?
NCT02687542 is a clinical study titled "Efficacy, Safety and Tolerability of PF-06649751 in Parkinson's Disease Patients With Motor Fluctuations". The purpose of this study is to evaluate the efficacy, safety and tolerability of PF-06649751 in Parkinson's disease patients who experience motor-fluctuations.
What is the current status of trial NCT02687542?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 108 participants. The study started on 2016-03-03. Estimated completion is 2017-11-10.
What interventions are being tested in trial NCT02687542?
The interventions under investigation include: Placebo (DRUG), PF-06649751 low dose (1 mg QD) (DRUG), PF-06649751 middle dose 1 (3 mg QD) (DRUG), PF-06649751 middle dose 2 (7 mg QD) (DRUG), PF-06649751 high dose (15 mg QD) (DRUG).
Who is sponsoring clinical trial NCT02687542?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.